CA-DIVERSIFIED-NANO
28.9.2018 14:52:06 CEST | Business Wire | Press release
Diversified Nano Solutions Corp launches revolutionary smartINK™ solutions to deliver the next generation of functional security printing to brand owners in any industry, institutions and individuals.
For the first time functional content printing and total security are delivered simultaneously and cost effectively by integrating copy-proof, unique and customer-specific smartQR™ biomarkers (watch video ) with the whole spectrum of digital inks.
Breakthrough smartINK ™ provides print and instant product identity and location tracking, at unbelievably low cost, on-the-spot, anywhere, anytime, by anyone.
Counterfeiting and illicit trade are pervasive in nearly every industry sector, harming consumers and brand owners, while costing the global economy over 1 trillion dollars annually.
Preservation of product and information integrity is increasingly important as sophisticated counterfeiting efforts easily defeat existing anti-counterfeit technologies.
smartINK™ makes it fun and easy to verify item integrity while establishing trust and defending item value. The smartINK™ solution scales easily, so individual brand owners and large enterprises alike can grow market share and successfully eliminate illicit trade and counterfeiting. Unbelievably low implementation costs enable fast payback and rapid deployment of secure mobile authentication and tracking worldwide.
As an expansion beyond digital print, DNSC is powering INKcrypt® smartQR™ available at www.goinkcrypt.com . FDA-compliant INKcrypt® smartQR™ enables tagging and marking of any physical object with traces of custom biomarkers using a variety of methods – including spray, brush, roll, flexo, offset and more.
Contact https://inkcryptink.com/ContactUs.aspx for details and to coordinate implementation of your smartINK™ and INKcrypt® smartQR™ solution.
smartINK™ solutions are compatible with inkjet platforms offered by Canon®, Screen®, Epson®, Ricoh®, HP®, FujiFilm®, Xerox®, Kyocera®, Konica Minolta® and more. Visit booth 829 at PRINT 18 September 30-October 2, 2018, in Chicago.
About DNSC
Diversified Nano Solutions Corporation (DNSC) , based in San Diego, California, specializes in developing, manufacturing and marketing high-performance inkjet inks and revolutionary, industry-unique smartINK™ solutions. Utilizing customer-specific INKcrypt® xDNA biomarker technology, smartINK™ provides total product & document security, proof of identity and worldwide tracking, anytime anywhere, at incredibly low cost. smartINK™ combines INKcrypt® xDNA™ biomarkers, the power of the internet and DNSC’s extensive product line of inks including CMYK , MICR (Magnetic Ink Character Recognition), invisible UV fluorescent / IR absorbing , spot and custom formulations .
Accessories and Security
DNSC supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and smartINK™ solutions. These include specialty substrates, smartQR™ biomarker authentication testers, UV display lights, INKVERSE ™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome ™ – an invisible color image generator to transform visible CMYK into invisible UV fluorescent red, green, blue, and white (RGBW) output, and more.
DNSC is presenting smartINK™ solutions, INKcrypt® smartQR™ and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.
Visit us at booth 829 and discover the future of digital ink: functional, secure, trackable, differentiating!
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005061/en/
Contact:
For more information: Diversified Nano Solutions Corporation Linda Meyers US Headquarters: +1.858.924.1005 EMEA: +41.41 874 08 50 info@diversifiednano.com www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom